Michael J. Surace

Oncology R&D
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI).

Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI).

Journal: Journal for immunotherapy of cancer

Published: August 27, 2025

Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High CST2 Expression and a Favorable Prognosis.

Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High CST2 Expression and a Favorable Prognosis.

Journal: Cancer research communications

Published: March 14, 2025

Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing.

Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing.

Journal: Journal for immunotherapy of cancer

Published: November 12, 2024

Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoring.

Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoring.

Journal: Frontiers in immunology

Published: April 23, 2024

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.

Journal: Nature communications

Published: July 10, 2023

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.

Journal: Cancer discovery

Published: April 21, 2023

Cellular inhibitor of apoptosis 2 (cIAP2) restricts neuroinflammation during experimental autoimmune encephalomyelitis.

Cellular inhibitor of apoptosis 2 (cIAP2) restricts neuroinflammation during experimental autoimmune encephalomyelitis.

Journal: Journal of neuroinflammation

Published: February 09, 2022

Characterization of the immune microenvironment of NSCLC by multispectral analysis of multiplex immunofluorescence images.

Characterization of the immune microenvironment of NSCLC by multispectral analysis of multiplex immunofluorescence images.

Journal: Methods in enzymology

Published: March 04, 2020

The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation.

The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation.

Journal: Journal for immunotherapy of cancer

Published: January 09, 2020

RelB controls adaptive responses of astrocytes during sterile inflammation.

RelB controls adaptive responses of astrocytes during sterile inflammation.

Journal: Glia

Published: April 27, 2018

Atypical microglial response to biodiesel exhaust in healthy and hypertensive rats.

Atypical microglial response to biodiesel exhaust in healthy and hypertensive rats.

Journal: Neurotoxicology

Published: June 01, 2016

RelB/p50 complexes regulate cytokine-induced YKL-40 expression.

RelB/p50 complexes regulate cytokine-induced YKL-40 expression.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: February 15, 2015

Showing 1-12 of 15

Last Updated: 09/26/2026